சந்தை வாய்ப்பு அழைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth
From TakedaDec 10 2020
As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade. The company also shared its PTS adjusted view for FY2019-FY2030 revenue CAGR (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to JPY5 trillion ($47 billion) by FY2030.
The majority of this revenue growth is expected to come from the company’s Wave 1 pipeline, which includes 12 unique New Molecular Entities (NMEs), representing potential best-in-class/first-in-class therapies, and its existing 14 global brands. Of the Wave 1 programs, five have received Breakthrough Therapy designation and three were granted fast track designation by the U.S. Food and D ....

Christophe Weber , Japanese Ministry Of Health , Takeda Pharmaceutical Company Limited , Drug Administration , Market Opportunity Call , New Molecular Entities , Breakthrough Therapy , Japanese Ministry , China Food , கிறிஸ்டோஃப் வெபர் , ஜப்பானிய அமைச்சகம் ஆஃப் ஆரோக்கியம் , டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை , சந்தை வாய்ப்பு அழைப்பு , புதியது மூலக்கூறு நிறுவனங்கள் , திருப்புமுனை சிகிச்சை , ஜப்பானிய அமைச்சகம் , சீனா உணவு ,